Arcus Biosciences (NYSE: RCUS) — Research Snapshot as of 2026-10-26

Company profile. Arcus Biosciences is a (largely "late") clinical-stage biopharmaceutical company headquartered in Hayward, California, developing cancer and immune-disease therapies. It trades on the NYSE under ticker RCUS (ISIN US03969F1093). [1] [20] [23] [25] As of late October 2026 the stock trades near ~$18.5–19.4 with a market capitalization of roughly ~$2.33B–$2.63B depending on the share count used. [12] [22] [23] [25]

Recent Catalysts (last ~1–3 months)